BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

748 related articles for article (PubMed ID: 21782884)

  • 1. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
    Ozkan EE
    Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine.
    Hewish M; Chau I; Cunningham D
    Recent Pat Anticancer Drug Discov; 2009 Jan; 4(1):54-72. PubMed ID: 19149688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-Like Growth Factor (IGF) family and prostate cancer.
    Gennigens C; Menetrier-Caux C; Droz JP
    Crit Rev Oncol Hematol; 2006 May; 58(2):124-45. PubMed ID: 16387509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of IGF signaling and the androgen receptor in prostate cancer progression.
    Wu JD; Haugk K; Woodke L; Nelson P; Coleman I; Plymate SR
    J Cell Biochem; 2006 Oct; 99(2):392-401. PubMed ID: 16639715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
    Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
    Höpfner M; Baradari V; Huether A; Schöfl C; Scherübl H
    Endocr Relat Cancer; 2006 Mar; 13(1):135-49. PubMed ID: 16601284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors.
    Scartozzi M; Bianconi M; Maccaroni E; Giampieri R; Del Prete M; Berardi R; Cascinu S
    Discov Med; 2011 Feb; 11(57):144-53. PubMed ID: 21356169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
    Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).
    Nickerson T; Chang F; Lorimer D; Smeekens SP; Sawyers CL; Pollak M
    Cancer Res; 2001 Aug; 61(16):6276-80. PubMed ID: 11507082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.
    Maloney EK; McLaughlin JL; Dagdigian NE; Garrett LM; Connors KM; Zhou XM; Blättler WA; Chittenden T; Singh R
    Cancer Res; 2003 Aug; 63(16):5073-83. PubMed ID: 12941837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors.
    Scagliotti GV; Novello S
    Cancer Treat Rev; 2012 Jun; 38(4):292-302. PubMed ID: 21907495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines.
    Attias-Geva Z; Bentov I; Fishman A; Werner H; Bruchim I
    Gynecol Oncol; 2011 May; 121(2):383-9. PubMed ID: 21295335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts.
    Goel HL; Breen M; Zhang J; Das I; Aznavoorian-Cheshire S; Greenberg NM; Elgavish A; Languino LR
    Cancer Res; 2005 Aug; 65(15):6692-700. PubMed ID: 16061650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.
    Rowinsky EK; Youssoufian H; Tonra JR; Solomon P; Burtrum D; Ludwig DL
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5549s-5555s. PubMed ID: 17875788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
    Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL
    Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer.
    Heidegger I; Massoner P; Sampson N; Klocker H
    Cancer Lett; 2015 Oct; 367(2):113-21. PubMed ID: 26231734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.
    Höpfner M; Huether A; Sutter AP; Baradari V; Schuppan D; Scherübl H
    Biochem Pharmacol; 2006 May; 71(10):1435-48. PubMed ID: 16530734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer.
    Furukawa J; Wraight CJ; Freier SM; Peralta E; Atley LM; Monia BP; Gleave ME; Cox ME
    Prostate; 2010 Feb; 70(2):206-18. PubMed ID: 19790231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis.
    Moser C; Schachtschneider P; Lang SA; Gaumann A; Mori A; Zimmermann J; Schlitt HJ; Geissler EK; Stoeltzing O
    Eur J Cancer; 2008 Jul; 44(11):1577-86. PubMed ID: 18445520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.